Remicade

Janssen Biotech, a subsidiary of Johnson & Johnson, is a leading biopharmaceutical company specializing in immunology, oncology, and cardiovascular diseases. The company is most notably recognized for developing Remicade (infliximab), a pioneering TNF-alpha inhibitor that revolutionized the treatment of chronic inflammatory conditions. Originally founded as Centocor in 1979, the firm was acquired by Johnson & Johnson in 1999 and later merged with Ortho Biotech to form its current entity. Today, Janssen Biotech manages a robust portfolio of blockbusters and next-generation therapies, maintaining a significant presence in the global biologics market through continuous innovation in monoclonal antibodies and cell therapies.